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BACKGROUND—Despite renewed focus on molecular tuberculosis (TB) diagnostics and new
antimycobacterial agents, treatment outcomes for patients co-infected with drug-resistant TB and
human immunodeficiency virus (HIV) remain dismal, in part due to lack of focus on medication
adherence as part of a patient-centered continuum of care.
OBJECTIVE—To review current barriers to drug-resistant TB-HIV treatment and propose an
alternative model to conventional approaches to treatment support.
DISCUSSION—Current national TB control programs rely heavily on directly observed therapy
(DOT) as the centerpiece of treatment delivery and adherence support. Medication adherence and
care for drug-resistant TB-HIV could be improved by fully implementing team-based patientcentered care, empowering patients through counseling and support, maintaining a rights-based
approach while acknowledging the responsibility of health care systems in providing
comprehensive care, and prioritizing critical research gaps.
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CONCLUSION—It is time to re-invent our understanding of adherence in drug-resistant TB and
HIV by focusing attention on the complex clinical, behavioral, social, and structural needs of
affected patients and communities.
Keywords
drug-resistant TB; HIV; medication adherence; patient-centered care
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APPROXIMATELY 1.5 MILLION people are living with multidrug-resistant tuberculosis
(MDR-TB) worldwide. While the overall TB epidemic is very slowly being brought under
control, the number of TB patients with drug-resistant TB (DR-TB) continues to rise. In
2013 alone, the World Health Organization (WHO) estimated that 480 000 individuals
developed MDR-TB, an increase of 80% from 2000 estimates.1 Globally, MDR-TB is
associated with human immunodeficiency virus (HIV) infection,2 and HIV exacerbates TB
clinically and in terms of social impact.3 In South Africa, the epicenter of the drug-resistant
TB-HIV syndemic, up to 80% of patients with extensively drug-resistant TB (XDR-TB) are
HIV co-infected. Even in low HIV burden countries, the proportion of DR-TB patients with
HIV co-infection ranges between 7% and 23%.4,5
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Treatment of DR-TB in low- and middle-income settings is fraught with clinical, operational
and social challenges. Patients with DR-TB/HIV take an average of six antimycobacterial
medications for >18 months in addition to lifelong antiretroviral therapy (ART). Treatment
is often centralized, and involves social marginalization, family isolation, difficult and
painful treatment regimens, dual stigmatization, and economic loss.3,6,7 In contrast, drugsusceptible TB is typically treated over a period of 6 months, with far fewer and far less
toxic medications, through largely decentralized channels of care. While recent innovations
in TB diagnostics, such as the Xpert® MTB/RIF assay (Cepheid, Sunnyvale, CA, USA),
have enhanced MDR-TB case detection, cure rates remain appallingly low.1 Poor treatment
outcomes have a number of potential causes. Low levels of medication adherence are
predicted to be an important cause of treatment failure,8,9 and are strongly associated with
failure to convert TB culture to negative during treatment.8–10
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Medication adherence in ART has been carefully studied.11 Each medication has a defined
adherence-resistance relationship, which is a function of the potency of the medication and
replicative capacity of drug-resistant organisms. Time on ART as well as patterns of
treatment interruptions also influence drug resistance-induced treatment failure.11–13 In
contrast to HIV, medication adherence in DR-TB-HIV is substantially understudied.14–18
Preliminary research from South Africa finds that XDR-TB/HIV co-infected patients report
significantly lower adherence to TB medications than ART.10 High ART adherence with low
TB medication adherence may improve patient survival without improving TB treatment
outcomes,19 and contribute to ongoing transmission.
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Although the WHO has endorsed more progressive approaches, such as the International
Standards for Tuberculosis Care,20,21 the reality is that anti-tuberculosis treatment programs
around the world focus on directly observed therapy (DOT) as the centerpiece of treatment
delivery and adherence support. As an isolated intervention, DOT lacks a rigorous evidence
base and is often at odds with patient needs and preferences.3,22–24 From the health systems
perspective, DOT programs may integrate poorly into health systems, face technical
challenges and variability of access, and poorly address stigma.24–26 To improve adherence
in DR-TB/HIV, there is an urgent need to evaluate patient-centered care approaches that look
beyond DOT, in particular its conventional facility-based form. Although HIV care delivery
can inform future advances in TB management, long-term HIV management itself requires
paradigm shifts from centralized to decentralized, patient-focused approaches that address
the waiting times for ART refills, improved management of medical complications,
transportation barriers, and burden on the strained health care workforce.25
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A patient-centered approach to adherence in DR-TB and HIV treatment that reflects the
Institute of Medicine (Washington DC, USA) recommendation for ‘partnership among
practitioners, patients, and their families (when appropriate) to ensure that decisions respect
patients’ wants, needs, and preferences and that patients have the education and support they
need to make decisions and participate in their own care’ is imperative.26,27 In other words,
not only should we recognize the time, cost and quality of health care services, we should
also consider the patient’s perspective and build on patient-provider relationships to enhance
the humaneness of care through communication, shared decision-making and support for
self-management. Patient-centered care has been shown to have positive effects on patient
behavior, well-being, and treatment outcomes.28 For treatment of DR-TB and HIV,
successful programs have included important elements of patient-centered care, including
emphasizing patient preference; decentralized, community-based care;29 and intensive
counseling, accompaniment,30 and support; while programs using mostly conventional
models of care have shown poor outcomes.31
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We conceptualize patient-centered care as being oriented toward addressing patients’
priorities, not in the sense of a menu of choices, but rather as a holistic model of health care
delivery that considers the patient as the central figure in the process or continuum of care. A
patient-centered approach is therefore not a one-size-fits-all solution to the multifactorial
patient-related barriers to MDR/XDR-TB/HIV treatment adherence that have been
identified, including high TB pill burden and adverse drug effects, lack of patient education
and counseling, provider supervision of anti-tuberculosis treatment, inability to access care
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in the community, and the stigma of public TB notification.3,7,10 Conversely, a patientcentered approach is a flexible model of care that reacts to the specialized needs of
individuals. Studies of DR-TB/HIV co-infected patients have identified HIV-specific
services as facilitators of ART adherence, including treatment literacy counseling, patient
involvement in care, and simpler drug regimens.3,32
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Patient-centered care depends on engaging each individual patient with tailored education/
counseling, understanding their motivations, and enhancing behavioral skills within the
context of local social, structural and cultural factors. A patient-centered approach is
particularly critical in vulnerable and marginalized MDR-/XDR-TB patients. The current
model of care in much of the world, which relies on a clinician to examine the MDRTB/HIV patient and prescribe TB medications without input from counselors, social workers
or mental health professionals, much less patients, addresses very little of this vulnerability.
A team-based approach that includes mental health trained providers, social work trained
providers, and behavioral counselors who can engage with patients more directly and
holistically, and explicitly integrates HIV and DR-TB care, allows us to think about and
make treatment decisions that encompass the full range of clinical, socio-economic and
structural issues confronting patients.
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Patient-centered approaches recognize that comprehensive care must be provided along a
locally contextualized continuum of services. The continuum or cascade of care for DRTB/HIV describes the complex, integrated steps from diagnosis to cure. In DR-TB/HIV, this
should incorporate early TB diagnosis and drug susceptibility testing, early HIV diagnosis,
comprehensive patient education and support, infection control, streamlined entry into cotreatment, unimpeded access to medications, adherence support, and retention in dual care.
For patients cured of DR-TB, the cascade should conclude with support for reintegration
back into the community, family life, and employment. For patients with disease considered
incurable, it must include palliative care (Figure). The decline between steps in the
continuum represents patient attrition, and underscores the need to improve care and
retention at each step.
In March 2015, a meeting of clinicians, behavioral and social scientists, patients, and
activists convened at the Mailman School of Public Health, Columbia University, New York,
NY, USA, to generate a call to action for patient-centered care in the treatment of DR-TB/
HIV. We commit to working with affected communities to improve medication adherence by
re-inventing models of care delivery that respect and address patients’ needs. This
commitment is based on the following principles that emerged from the 2015 symposium:
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1.

Patient-centered care is team-based, decentralized care that requires substantial
investment in human resources to provide high-quality care in settings where
patients live and work, and are connected to networks of social capital and social
support.

2.

Patient education and counseling—with the goals of patient empowerment,
treatment literacy, accountability, and reducing stigma—should be at the heart of
adherence support for DR-TB/HIV. Core standards in counseling and education for

Int J Tuberc Lung Dis. Author manuscript; available in PMC 2016 May 11.

O’Donnell et al.

Page 5

Author Manuscript

DR-TB/HIV need to be developed, as education and DOT may have different
meanings and are implemented differently throughout the world.
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3.

Public health approaches to DR-TB/HIV should be based on human rights and
equity. Where public health and individual rights conflict—for example, the
forcible detention or isolation of people with infectious XDR-TB to protect others
from transmission—a rights-based approach will use deliberation in accordance
with the Siracusa Principles33 to justify rights-limiting public health measures.

4.

Patient-centered care does not mean centering all responsibility on the person with
TB. Grounding patient-centered care in rights-based approaches recognizes that
governments and health systems must bear the responsibility to respect, protect,
and fulfill the right to health along the cascade of care.

5.

There are critical research gaps in understanding the cascade of care for DR-TB/
HIV, including biomedical, behavioral, and implementation science components.
This research agenda must be urgently prioritized in parallel with operationalizing
patient-centered practices, and donors should commit to funding this research.

The development of new TB diagnostics, drugs, and treatment regimens presents exciting
opportunities to improve outcomes and reduce community transmission of DR-TB. With
innovative and effective approaches to patient-centered care, the opportunity to impact the
epidemic afforded by new diagnostics and drugs may not be realized. It is time for
clinicians, researchers and TB practitioners to re-invent the understanding of adherence in
DR-TB/HIV to eliminate disease and stigma by focusing efforts and attention on affected
patients and communities.
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Figure.
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The continuum of DR-TB/HIV care defines the processes and linkages that comprise
optimal care for MDR-/XDR-TB/HIV. The y-axis represents patients retained in care; the xaxis represents the stages of the continuum; the arrows represent the linkages in the
continuum. The box below defines tasks and processes that occur at each stage. TB =
tuberculosis; HIV = human immunodeficiency virus; DR-TB = drug-resistant TB; VL =
viral load; DST = drug susceptibility testing; MDR-TB = multidrug-resistant TB; XDR-TB
= extensively drug-resistant TB. This image can be viewed online in colour at http://
www.ingentaconnect.com/content/iuatld/ijtld/2016/00000020/00000004/art00004
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